Galapagos NV (GLPGF)
USD 26.26
(0.0%)
USD 26.26
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 211.69 Million EUR | 197.11% |
| 2022 | -217.99 Million EUR | -111.17% |
| 2021 | -103.23 Million EUR | 66.2% |
| 2020 | -305.43 Million EUR | -303.83% |
| 2019 | 149.84 Million EUR | 612.13% |
| 2018 | -29.25 Million EUR | 74.71% |
| 2017 | -115.7 Million EUR | -314.22% |
| 2016 | 54.01 Million EUR | 145.61% |
| 2015 | -118.41 Million EUR | -456.54% |
| 2014 | 33.21 Million EUR | 511.08% |
| 2013 | -8.07 Million EUR | -41.22% |
| 2012 | -5.72 Million EUR | 82.71% |
| 2011 | -33.09 Million EUR | -857.37% |
| 2010 | 4.37 Million EUR | 45.18% |
| 2009 | 3.01 Million EUR | 120.64% |
| 2008 | -14.58 Million EUR | 33.55% |
| 2007 | -21.94 Million EUR | -93.63% |
| 2006 | -11.33 Million EUR | -73.29% |
| 2005 | -6.54 Million EUR | -82.25% |
| 2004 | -3.58 Million EUR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | 8.98 Million EUR | -90.04% |
| 2024 Q1 | 90.22 Million EUR | -42.74% |
| 2023 Q3 | 25.83 Million EUR | 406.37% |
| 2023 FY | 211.69 Million EUR | 197.11% |
| 2023 Q1 | 23.2 Million EUR | 111.2% |
| 2023 Q2 | 5.1 Million EUR | -78.02% |
| 2023 Q4 | 157.55 Million EUR | 509.98% |
| 2022 Q2 | -19.02 Million EUR | -42.96% |
| 2022 Q1 | -13.31 Million EUR | -181.41% |
| 2022 FY | -217.99 Million EUR | -111.17% |
| 2022 Q4 | -207.2 Million EUR | -1061.34% |
| 2022 Q3 | 21.55 Million EUR | 213.28% |
| 2021 FY | -103.23 Million EUR | 66.2% |
| 2021 Q2 | -64.32 Million EUR | -787.2% |
| 2021 Q4 | 16.35 Million EUR | 125.3% |
| 2021 Q3 | -64.61 Million EUR | -0.44% |
| 2021 Q1 | 9.36 Million EUR | 116.17% |
| 2020 Q2 | -115.04 Million EUR | -127.35% |
| 2020 Q4 | -57.88 Million EUR | 29.32% |
| 2020 FY | -305.43 Million EUR | -303.83% |
| 2020 Q1 | -50.6 Million EUR | 56.18% |
| 2020 Q3 | -81.9 Million EUR | 28.8% |
| 2019 Q2 | -47.24 Million EUR | 2.89% |
| 2019 Q1 | -48.65 Million EUR | -425.33% |
| 2019 FY | 149.84 Million EUR | 612.13% |
| 2019 Q4 | -115.48 Million EUR | -131.97% |
| 2019 Q3 | 361.23 Million EUR | 864.53% |
| 2018 Q2 | -21.77 Million EUR | 41.6% |
| 2018 Q4 | 14.95 Million EUR | 0.77% |
| 2018 FY | -29.25 Million EUR | 74.71% |
| 2018 Q3 | 14.84 Million EUR | 168.16% |
| 2018 Q1 | -37.28 Million EUR | -24.91% |
| 2017 Q2 | -35.64 Million EUR | -161.98% |
| 2017 Q1 | -13.6 Million EUR | -129.61% |
| 2017 FY | -115.7 Million EUR | -314.22% |
| 2017 Q3 | -36.6 Million EUR | -2.71% |
| 2017 Q4 | -29.84 Million EUR | 18.46% |
| 2016 Q2 | -3.72 Million EUR | -110.35% |
| 2016 Q1 | 35.95 Million EUR | 163.07% |
| 2016 Q3 | -24.16 Million EUR | -549.34% |
| 2016 FY | 54.01 Million EUR | 145.61% |
| 2016 Q4 | 45.94 Million EUR | 290.15% |
| 2015 FY | -118.41 Million EUR | -456.54% |
| 2015 Q4 | -57 Million EUR | -109.4% |
| 2015 Q3 | -27.22 Million EUR | -36.42% |
| 2015 Q2 | -19.95 Million EUR | -40.27% |
| 2015 Q1 | -14.22 Million EUR | -38.15% |
| 2014 FY | 33.21 Million EUR | 511.08% |
| 2014 Q4 | -10.29 Million EUR | 16.66% |
| 2014 Q3 | -12.35 Million EUR | -69.03% |
| 2014 Q1 | -7.31 Million EUR | -34.82% |
| 2014 Q2 | -7.31 Million EUR | 0.0% |
| 2013 FY | -8.07 Million EUR | -41.22% |
| 2013 Q1 | -2.98 Million EUR | 0.0% |
| 2013 Q2 | -2.98 Million EUR | 0.0% |
| 2013 Q4 | -5.42 Million EUR | 0.0% |
| 2013 Q3 | -5.42 Million EUR | -81.78% |
| 2012 Q2 | - EUR | 0.0% |
| 2012 FY | -5.72 Million EUR | 82.71% |
| 2011 FY | -33.09 Million EUR | -857.37% |
| 2011 Q2 | - EUR | 0.0% |
| 2010 Q2 | - EUR | 0.0% |
| 2010 FY | 4.37 Million EUR | 45.18% |
| 2009 Q2 | - EUR | 0.0% |
| 2009 FY | 3.01 Million EUR | 120.64% |
| 2008 FY | -14.58 Million EUR | 33.55% |
| 2007 FY | -21.94 Million EUR | -93.63% |
| 2006 FY | -11.33 Million EUR | -73.29% |
| 2005 FY | -6.54 Million EUR | -82.25% |
| 2004 FY | -3.58 Million EUR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | 382.402% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | 3319.182% |
| SQZ Biotechnologies Company | -79.46 Million USD | 366.406% |
| Evofem Biosciences, Inc. | 52.97 Million USD | -299.587% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | -225.023% |
| Mesoblast Limited | -87.95 Million USD | 340.685% |
| Propanc Biopharma, Inc. | -1.82 Million USD | 11728.33% |
| Genus plc | 7.9 Million USD | -2579.709% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | 2043.647% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | 5805.759% |
| Marizyme, Inc. | -65.34 Million USD | 423.959% |
| ContraFect Corporation | -65.15 Million USD | 424.923% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | 2493.679% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | 4432.67% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | 12354.849% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | 7419.093% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | 2726.617% |
| MultiCell Technologies, Inc. | -380.07 USD | 55699576.412% |
| Accustem Sciences Inc. | -3.74 Million USD | 5750.649% |
| RVL Pharmaceuticals plc | -51.69 Million USD | 509.535% |
| EV Biologics, Inc. | -1.26 Million USD | 16806.757% |
| Q BioMed Inc. | -2.05 Million USD | 10416.15% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | 5770.962% |
| Neon Bloom, Inc. | -632.4 Thousand USD | 33574.803% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | 8991.582% |
| Biomind Labs Inc. | -1.21 Million USD | 17533.393% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | -10.54 Million USD | 2106.987% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | 2778.66% |
| Skye Bioscience, Inc. | -37.64 Million USD | 662.354% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | 9856.458% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | 1413675.053% |
| Arch Therapeutics, Inc. | -6.98 Million USD | 3131.677% |
| IMV Inc. | -36.48 Million USD | 680.219% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | 1433.823% |
| Curative Biotechnology, Inc. | -5.81 Million USD | 3739.123% |
| GB Sciences, Inc. | -1.36 Million USD | 15646.785% |
| Alpha Cognition Inc. | -13.77 Million USD | 1637.092% |
| HST Global, Inc. | -146.21 Thousand USD | 144889.686% |
| CSL Limited | 2.64 Billion USD | 91.987% |
| Halberd Corporation | -79.67 Thousand USD | 265797.324% |
| Enzolytics Inc. | -2.17 Million USD | 9825.004% |
| Resverlogix Corp. | -3.61 Million USD | 5964.183% |
| Affymax, Inc. | -14.42 Million USD | 1567.672% |
| SYBLEU INC | -180.3 Thousand USD | 117511.15% |
| Nuo Therapeutics, Inc. | -3.17 Million USD | 6775.115% |
| argenx SE | -295.05 Million USD | 171.749% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | 438.18% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | -215917.347% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | 5428.401% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | 7095.623% |
| AVAX Technologies, Inc. | -6.41 Million USD | 3400.727% |
| Zenith Capital Corp. | -10.59 Million USD | 2097.895% |
| Genscript Biotech Corporation | -95.47 Million USD | 321.726% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | 910938.138% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | 5206.133% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | 350356.227% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | 454.451% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | 6925.043% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | -1.05 Million USD | 20145.982% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | 10960.439% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | -3.81 Million USD | 5643.257% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | 10657.848% |
| BioStem Technologies, Inc. | -8.48 Million USD | 2595.549% |
| ONE Bio Corp. | 8.67 Million USD | -2339.858% |
| Reve Technologies, Inc. | -441.36 Thousand USD | 48063.722% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | 15952.335% |
| Wesana Health Holdings Inc. | -1.75 Million USD | 12164.081% |
| Agentix Corp. | -1.37 Million USD | 15504.985% |
| LadRx Corporation | 400.44 Thousand USD | -52765.701% |
| Cell Source, Inc. | -5.32 Million USD | 4078.361% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | 51052.515% |
| Regen BioPharma, Inc. | 1.02 Million USD | -20583.473% |
| Regen BioPharma, Inc. | 1.02 Million USD | -20583.473% |
| NovAccess Global Inc. | -4.76 Million USD | 4538.849% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | -2957.176% |
| Itoco Inc. | -1.86 Million USD | 11426.783% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | 4865.23% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | 12784.062% |
| Kadimastem Ltd | -3.3 Million USD | 6500.711% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | 77530.67% |
| CytoDyn Inc. | -49.84 Million USD | 524.745% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | 267958.996% |
| Mobile Lads Corp. | -2.26 Million USD | 9453.499% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | 92897.871% |
| Qrons Inc. | -789.34 Thousand USD | 26919.257% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | 22584.384% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | -2.08 Million USD | 10240.29% |
| Rebus Holdings, Inc. | -1.02 Million USD | 20854.608% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | 13226.567% |
| International Stem Cell Corporation | -131 Thousand USD | 161700.763% |
| Bioxytran, Inc. | -4.28 Million USD | 5046.189% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | 390166.701% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | 8466.654% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | -48.07 Million USD | 540.375% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | 10114.049% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | -780.88 Thousand USD | 27209.812% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | 6782.355% |
| Neutra Corp. | -233.46 Thousand USD | 90776.118% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | 1143.305% |
| PureTech Health plc | -65.69 Million USD | 422.232% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | 1095.447% |
| IXICO plc | -1.17 Million USD | 18070.883% |
| IntelGenx Technologies Corp. | -9.92 Million USD | 2232.538% |
| Gelesis Holdings, Inc. | -57.12 Million USD | 470.566% |
| CSL Limited | 2.64 Billion USD | 91.987% |
| Cellectis S.A. | -103.17 Million USD | 305.185% |